M&T Bank Corp Buys New Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

M&T Bank Corp purchased a new position in shares of Option Care Health, Inc. (NASDAQ:OPCH) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 5,921 shares of the company’s stock, valued at approximately $207,000.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Option Care Health by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company’s stock worth $448,118,000 after buying an additional 75,313 shares during the period. Wellington Management Group LLP lifted its stake in shares of Option Care Health by 84.6% in the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company’s stock worth $425,143,000 after buying an additional 8,400,208 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Option Care Health by 17.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company’s stock worth $92,518,000 after purchasing an additional 591,042 shares in the last quarter. Northern Trust Corp lifted its position in Option Care Health by 11.8% during the fourth quarter. Northern Trust Corp now owns 2,626,478 shares of the company’s stock worth $60,934,000 after buying an additional 278,158 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Option Care Health during the 4th quarter valued at about $60,219,000. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on OPCH shares. UBS Group raised Option Care Health from a “neutral” rating to a “buy” rating and upped their price target for the company from $38.00 to $40.00 in a research note on Wednesday, April 30th. JMP Securities restated a “market outperform” rating and set a $36.00 price target on shares of Option Care Health in a report on Wednesday, June 18th. Finally, Barrington Research restated an “outperform” rating and issued a $38.00 price objective on shares of Option Care Health in a report on Thursday, July 10th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.50.

Option Care Health Price Performance

Shares of NASDAQ OPCH opened at $29.48 on Friday. The stock has a 50 day moving average of $31.58 and a two-hundred day moving average of $31.61. Option Care Health, Inc. has a twelve month low of $21.39 and a twelve month high of $35.53. The stock has a market cap of $4.83 billion, a P/E ratio of 23.77, a P/E/G ratio of 1.81 and a beta of 0.73. The company has a current ratio of 1.54, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82.

Option Care Health (NASDAQ:OPCH) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period in the prior year, the business earned $0.26 EPS. The firm’s revenue was up 16.3% compared to the same quarter last year. On average, research analysts forecast that Option Care Health, Inc. will post 1.22 earnings per share for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.